August 17, 2004

ATTN:  Medical Health Officers and Branch Offices
       Public Health Nursing Administrators and Assistant Administrators
       Holders of Communicable Disease Control Manuals

Re:  Revisions to Chapter III of the Communicable Disease Control Manual –
     “Immunization Program”

Please note the following revisions:

(1) Section I – Introduction:

Table of Contents:
   • change of term from Immunization Certification to Immunization Competency.

Page 4, Subsection 5.0 “Immunization Competency:”
   • change of term from “Immunization Certification” to “Immunization
     Competency.”
   • notation of the provincial Immunization Competency Program being revised
     in May 2004

Pages 5 – 9, Subsection 7.0 “History of Immunization Development in BC:”
   • re-dated due to additional content:

Page 6:
   • 1981 - regarding DPT, DT and Td adsorbed vaccines – notation that these
     vaccines contained thimerosal

Page 7:
   • 1994 – note that Pentavalent vaccine (diphtheria, pertussis, tetanus, polio,
     conjugate haemophilus influenzae type b) (DPT/IPV/ActHIB) did not contain
     thimerosal

Administrative Circular # 2004:05
Page 8:
- 1997 – added notation that a hepatitis B vaccine catch-up program was provided to all grade 12 students

Page 9:
- 2001 – Thimerosal-free HBV for infants and children < 7 years of age (June 2001)
- Addition of new vaccine programs introduced in 2004

Page 11:
- Pertussis toxoid 2.5 μg added to vaccine components list for TdaP

(2) Section V – Anaphylaxis:

Page 4: removal of oral Benadryl® use from guidelines
Page 7: addition of Epinephrine strength (1:1,000) to top of chart
Page 8: removal of oral Benadryl®

(3) Section VII – Biological Products:

Page 6, Hepatitis A Vaccine Indications:
- Inmates of provincial correctional facilities are eligible for hepatitis A vaccine.

Page 9, Hepatitis A Vaccine, Avaxim™:
- latex has been removed from the needle shield for this product.

Page 16, Hepatitis B Vaccine Pre-exposure, Engerix®-B:
- the schedule for infants and children < 7 years of age is 0, 1, and 6 months, (and not 2 – 4 - 6 months).

Page 17, Hepatitis B Vaccine Pre-exposure, Engerix®-B:
- deleted footnote regarding revaccination of non-responders.

Page 18, Hepatitis B Vaccine Pre-exposure, RecombivaxHB®:
- deleted footnote regarding revaccination of non-responders.
- deleted footnote regarding minimal intervals between vaccine doses.
Page 28, Immune Globulin Preparations:
- for children 5 to 18 years inclusive, added 1" - 1½" needle length, 20-25 gauge, vastus lateralis site and 1 – 3 ml volume
- for adults ≥ 19 years of age, added 1" - 1½" needle length, 20-22 gauge, vastus lateralis site and 5 ml volume.

Page 29, Immune Globulin Preparations or Blood: Timing Intervals:
- under “Indications” for measles prophylaxis, changed the wording from “normal contact” to “healthy contact”.

Page 32, Influenza Vaccine, Fluviral®S/F:
- wording has been changed to direct the reader to the National Advisory Committee on Immunization statement on influenza vaccination for the current season.

Page 34, Measles/Mumps/Rubella Vaccine:
- updated the list of components of MMRII™ vaccine.

Page 37, Meningococcal C Conjugate Vaccine, Neis Vac- C:
- change to the timing and number of doses of Neis Vac- C for infants: infants from two months to twelve months of age receive two doses of vaccine, two months apart.

Page 38, Meningococcal C Conjugate Vaccine, Neis Vac- C:
- change to vaccine doses and timing for infants from two to twelve months of age, as above.

Page 43, Pneumococcal Polysaccharide Vaccine, Pneumo 23™:
- latex has been removed from the needle shield for this product.

Page 43a, Pneumococcal Polysaccharide Vaccine, Pneumovax® 23:
- new page, for the Merck Frosst pneumococcal polysaccharide vaccine.

Page 53, Tetanus-Diphtheria-Pertussis Vaccine, Adacel™:
- footnote added to indicate that high school students who missed their grade 9 booster should be given Adacel™.

Page 54, Tetanus-Diphtheria-Inactivated Poliomyelitis Adsorbed (Td/IPV):
- clarification of the reinforcing vaccine dose (Td, 0.5 mL IM, every 10 years).
Page 55, Tetanus Immune Globulin (TIG), Baytet™:
  • added footnote indicating that TIG does not interfere with the development of active immunity from a tetanus-containing vaccine.

Please remove and destroy the following pages from Chapter III of the Communicable Disease Control Manual – “Immunization Program”:

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section I Introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table of Contents</td>
<td>Pages 4, 5, 6, 7 &amp; 8</td>
<td>Dated June 2003</td>
</tr>
<tr>
<td></td>
<td>Pages 9 &amp; 11</td>
<td>Dated November 2002</td>
</tr>
<tr>
<td>Section V Anaphylaxis:</td>
<td>Pages 4, 7 &amp; 8</td>
<td>Dated June 2003</td>
</tr>
<tr>
<td>Section VII Biological Products:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table of Contents</td>
<td>Pages 6, 34 &amp; 55</td>
<td>Dated July 2004</td>
</tr>
<tr>
<td></td>
<td>Pages 16 &amp; 18</td>
<td>Dated August 2003</td>
</tr>
<tr>
<td></td>
<td>Pages 17 &amp; 54</td>
<td>Dated June 2004</td>
</tr>
<tr>
<td></td>
<td>Pages 28, 37 &amp; 43</td>
<td>Dated November 2002</td>
</tr>
<tr>
<td></td>
<td>Pages 29 &amp; 38</td>
<td>Dated December 2003</td>
</tr>
<tr>
<td></td>
<td>Page 32</td>
<td>Dated June 2003</td>
</tr>
<tr>
<td></td>
<td>Page 53</td>
<td>Dated September 2003</td>
</tr>
</tbody>
</table>

Please insert the following replacement pages:

| Section I Introduction:          |                |                   |
| Table of Contents                | Pages 4, 5, 6, 7, 8, 9 & 11 | Dated August 2004 |
| Section V Anaphylaxis:          | Pages 4, 7 & 8, 9 | Dated August 2004 |
| Section VII Biological Products:|                |                   |
| Table of Contents                | Pages 6, 9, 16, 17, 18, 28, 29, 32, 34, 37, 38, 43, 43a, 53, 54 & 55 | Dated August 2004 |
If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604) 660-6061, fax (604) 660-0197 or by e-mail to karen.pielak@bccdc.ca or cheryl.mcintyre@bccdc.ca

Sincerely,

David Patrick
Director
Epidemiology Services
BC Centre for Disease Control

DMP/kka

pc: Dr Perry Kendall Dr. Eric Young
    Provincial Health Officer Deputy Provincial Health Officer
    Ministry of Health Services Ministry of Health Services

Dr. Bob Fisk Warren O’Briain
Medical Consultant Executive Director
Non-Communicable Disease Comm Disease and Addiction Prevention
Ministry of Health Planning Ministry of Health Services

Valery Dubenko
Manager, Communicable Disease Prevention --Immunization
Communicable Disease and Addiction Prevention
Ministry of Health Services